SCHEMBL5132384

SCHEMBL5132384

CNc1cc(CO)cc(OC)c1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
DAO P14920 1/20 0.41
KMT2A Q03164 2/20 0.41
POLB P06746 1/20 0.41
CALM1 P0DP23 3/20 0.39
L3MBTL1 Q9Y468 1/20 0.38
ALDH1A1 P00352 1/20 0.37
MAPT P10636 1/20 0.37
GRIN2D O15399 1/20 0.37
GRIN3B O60391 1/20 0.37
GRIN1 Q05586 1/20 0.37
GRIN2A Q12879 1/20 0.37
GRIN2B Q13224 1/20 0.37
GRIN2C Q14957 1/20 0.37
GRIN3A Q8TCU5 1/20 0.37
AKR1B1 P15121 1/20 0.36
CHRM2 P08172 1/20 0.36
CHRM1 P11229 1/20 0.36
CHRM3 P20309 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1621101 0.81 DAO (0.53) DAOCALM1ALDH1A1MAPTGRIN2D
SCHEMBL65276 0.81 ALDH1A1 (0.58) DAOCALM1ALDH1A1MAPTGRIN2D
SCHEMBL12126049 0.81 ACHE (0.42) MAPT
SCHEMBL28123040 0.79 ALDH1A1 (0.55) DAOCALM1ALDH1A1MAPTGRIN2D
SCHEMBL23665879 0.79 POLB (0.49) KMT2APOLBL3MBTL1ALDH1A1MAPT
SCHEMBL3931955 0.79 KMT2A (0.51) KMT2APOLBL3MBTL1ALDH1A1MAPT
SCHEMBL1547868 0.79 ALDH1A1 (0.61) KMT2APOLBL3MBTL1ALDH1A1MAPT
SCHEMBL1620230 0.76 GRIN2D (0.47) DAOCALM1ALDH1A1MAPTGRIN2D
SCHEMBL920598 0.75 ALDH1A1 (0.50) DAOCALM1ALDH1A1MAPTGRIN2D
SCHEMBL24951300 0.74 MAOB (0.46) DAOCALM1ALDH1A1AKR1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022253284-A1 DRUG CONJUGATE AND USE THEREOF 百奥泰生物制药股份有限公司 2022-12-08 WO disclosed
US-20080242663-A1 NOVEL PYRIMIDINE DERIVATIVES 698 ASTRAZENECA AB (SE) 2008-10-02 US disclosed
US-20080242663-A1 NOVEL PYRIMIDINE DERIVATIVES 698 ASTRAZENECA AB (SE) 2008-10-02 US disclosed
US-20080242663-A1 NOVEL PYRIMIDINE DERIVATIVES 698 ASTRAZENECA AB (SE) 2008-10-02 US disclosed
WO-2008104754-A1 NOVEL PYRIMIDINE DERIVATIVES 698 ASTRAZENECA AB (SE) 2008-09-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080242663-A1 NOVEL PYRIMIDINE DERIVATIVES 698 EPHB4, EPHB1, NME2 DAO 2774/4885KMT2A 2230/4885POLB 200/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.